CANTON, Mass., Sept. 5 /PRNewswire/ -- Avitar, Inc. (Amex: AVR) today
announced that it has been invited to make a presentation at IHS Health
Group's Emerging Medical Technologies East (EMT) Conference & Exhibition on
Thursday, Sept. 6, at 3:30 p.m. at the Hyatt Regency Hotel in Cambridge, MA.
Avitar will be one of approximately 40 companies presenting during the
two-day conference to an audience of investment professionals and industry
leaders. Following Avitar's presentation, the company will participate in a
breakout session for smaller group and one-on-one discussions. On Thursday
evening, there will be a reception/exhibition with a tabletop display of
products and literature.
This is the 5th annual Emerging Medical Technology Conference, and the
eighth year that EMT conferences have been held in both the U.S. and Europe,
to enable companies to potentially discuss areas such as financing, corporate
alliances, joint ventures and distribution agreements
"We look forward to presenting at the EMT East Conference this week, and
to be among the cutting-edge medical technology companies that will be in
attendance," said Peter P. Phildius, Avitar's Chairman and Chief Executive
Officer. "This conference is well-known for putting companies, as well as
investors, together to discuss areas of mutual interest."
ABOUT AVITAR
Avitar, Inc. (Amex: AVR) headquartered in Canton, Massachusetts, is a
diagnostics company that develops, manufactures and markets innovative and
proprietary medical devices in two major areas: the oral fluid drugs-of-abuse
market and the disease & clinical testing market. Oral fluid diagnostics
includes both the drugs-of-abuse testing market estimated to be worth $1.5
billion encompassing the corporate workplace and criminal justice markets.
Avitar's products include ORALscreen(TM), the world's first non-invasive,
rapid, onsite oral fluid test for drugs-of-abuse, and HAIRscreen(TM), a
laboratory-based hair test for detecting long-term drug abuse. In the $20
billion disease & clinical testing market, Avitar is currently developing
products that will address the conditions of Lyme disease, influenza and
diabetes, as well as pregnancy.
For more information, see Avitar's website at http://www.avitarinc.com.
This release contains forward looking statements that are subject to risks
and uncertainties including the development and marketing of new applications
and other risks that are detailed from time to time in the Company's filings
with the Securities and Exchange Commission.
SOURCE Avitar, Inc.
 back to top
Related links:
http://www.avitarinc.com
CONTACT:
Tara Wynn of Avitar, Inc., +1-781-821-2440;
or John Ingoldsby of Ingoldsby Investor Relations, Inc.,
+1-508-359-2280
|
